Promising RNA-based therapies for viral infections, genetic disorders, and cancer

Abstract

RNA-based treatments offer promising avenues for addressing various disorders by selectively targeting specific genes and pathways implicated in diseases. Central to these therapies is RNA interference (RNAi), a mechanism that enables the precise downregulation of gene expression by utilizing small interfering RNAs (siRNAs) to degrade target messenger RNAs (mRNAs). The unparalleled selectivity of RNAi, mediated by siRNAs, significantly reduces off-target effects, making it a highly precise therapeutic tool. This article provides a comprehensive review of diverse strategies for developing RNA-based therapeutic interventions including mRNA vaccines, siRNAs, and antisense oligonucleotides, each offering unique mechanisms for modulating gene expression. In the context of oncology, RNA-based interventions have the potential to offer a multifaceted approach, including the suppression of oncogenes, the presentation of tumor-specific antigens through mRNA vaccines, and the targeted delivery of treatments to cancerous cells using RNA aptamers. Despite their potential, RNA-based therapies currently face significant concerns that must be addressed to maximize their effectiveness. Some of these concerns include optimizing delivery methods to ensure efficient cellular uptake, enhancing the stability and longevity of therapeutic effects on targets and mitigating unintended side effects associated with treatment. The study concludes that RNA-based therapies hold considerable promise for personalized medicine and healthcare management; however, further research is needed to overcome existing concerns. This may involve refining the chemical compositions of RNA-based therapeutic approaches, potential combination with conventional treatments, and advanced delivery technologies. Sustained progress in these areas is crucial for continued advancements and improving patient outcomes using RNA-based therapeutic solutions.